J
Joshua Armenia
Researcher at AstraZeneca
Publications - 7
Citations - 284
Joshua Armenia is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 106 citations. Previous affiliations of Joshua Armenia include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Ying Z. Mazzu,Joshua Armenia,Joshua Armenia,Goutam Chakraborty,Yuki Yoshikawa,Si'Ana A. Coggins,Subhiksha Nandakumar,Travis Gerke,Mark Pomerantz,Xintao Qiu,Huiyong Zhao,Mohammad Omar Atiq,Nabeela Khan,Kazumasa Komura,Gwo-Shu Mary Lee,Samson W. Fine,Connor Bell,Edward P. O’Connor,Henry W. Long,Matthew L. Freedman,Baek Kim,Baek Kim,Philip W. Kantoff +22 more
TL;DR: It is proposed that increased expression of RRM2 is a mechanism driving poor patient outcomes in prostate cancer and that its inhibition may be of significant therapeutic value.
Journal ArticleDOI
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
TL;DR: It is suggested that pharmacological inhibition of DNA end-joining repair pathways could improve durability of drug treatments by preventing the acquisition of reversion mutations in BRCA genes.
Journal ArticleDOI
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Ben Sidders,Pei Zhang,Kelly Goodwin,Greg O'Connor,Deanna L. Russell,Alexandra Borodovsky,Joshua Armenia,Robert McEwen,Bolan Linghu,Johanna C. Bendell,Todd M. Bauer,Manish R. Patel,Gerald Steven Falchook,Melinda S. Merchant,Gayle Pageau Pouliot,J. Carl Barrett,Jonathan R. Dry,Richard Woessner,Kris Sachsenmeier +18 more
TL;DR: The adenosine pathway is supported as a mediator of a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosines pathway modulators currently in development.
Journal ArticleDOI
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
Lorenzo Ruffoni,R. Kim,M. Kwon,M. An,S.T. Kim,Simon Smith,A.B. Loembé,Peter G. Mortimer,Joshua Armenia,Natalia Lukashchuk,Neel Shah,Emma Dean,W. Park,J.W. Lee,J.W. Lee +14 more
Journal ArticleDOI
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
Claudia Winkler,Joshua Armenia,Gemma N Jones,Luis Tobalina,Matthew J. Sale,Tudor Petreus,Tarrion Baird,Violeta Serra,Anderson T. Wang,Alan Lau,Mathew J. Garnett,Patricia Jaaks,Elizabeth A. Coker,Andrew J. Pierce,Mark J. O'Connor,Elisabetta Leo +15 more
TL;DR: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors as mentioned in this paper, but not to non-DDA or DDRi therapies, such as WEE1 inhibitor or olaparib.